Search Results

There are 11983 results for: content related to: Tolvaptan

  1. You have free access to this content
    Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects

    British Journal of Clinical Pharmacology

    Volume 73, Issue 4, April 2012, Pages: 579–587, Susan E. Shoaf, Patricia Bricmont and Suresh Mallikaarjun

    Article first published online : 12 MAR 2012, DOI: 10.1111/j.1365-2125.2011.04114.x

  2. In Vitro P-Glycoprotein Interactions and Steady-State Pharmacokinetic Interactions Between Tolvaptan and Digoxin in Healthy Subjects

    The Journal of Clinical Pharmacology

    Volume 51, Issue 5, May 2011, Pages: 761–769, Dr Susan E. Shoaf, Mr Yoshihiro Ohzone, Dr Shin-ichi Ninomiya, Dr Masayuki Furukawa, Dr Patricia Bricmont, Dr Eiji Kashiyama and Dr Suresh Mallikaarjun

    Article first published online : 8 MAR 2013, DOI: 10.1177/0091270010376193

  3. You have full text access to this OnlineOpen article
    Substandard drugs: a potential crisis for public health

    British Journal of Clinical Pharmacology

    Volume 78, Issue 2, August 2014, Pages: 218–243, Atholl Johnston and David W. Holt

    Article first published online : 21 JUL 2014, DOI: 10.1111/bcp.12298

  4. Therapeutic effects of short- and intermediate-term tolvaptan administration for refractory ascites in patients with advanced liver cirrhosis

    Hepatology Research

    Shintaro Akiyama, Kenji Ikeda, Hitomi Sezaki, Taito Fukushima, Yushi Sorin, Yusuke Kawamura, Satoshi Saitoh, Tetsuya Hosaka, Norio Akuta, Masahiro Kobayashi, Fumitaka Suzuki, Yoshiyuki Suzuki, Yasuji Arase and Hiromitsu Kumada

    Article first published online : 6 JAN 2015, DOI: 10.1111/hepr.12455

  5. You have free access to this content
    Rilonacept and canakinumab

    British Journal of Clinical Pharmacology

    Volume 71, Issue 5, May 2011, Pages: 639–641, Eline A. Dubois, Robert Rissmann and Adam F. Cohen

    Article first published online : 11 APR 2011, DOI: 10.1111/j.1365-2125.2011.03958.x

  6. Pharmacokinetics, Pharmacodynamics, and Safety of Tolvaptan, a Nonpeptide AVP Antagonist, During Ascending Single-Dose Studies in Healthy Subjects

    The Journal of Clinical Pharmacology

    Volume 47, Issue 12, December 2007, Pages: 1498–1507, Susa E. Shoaf, Zhao Wang, Patricia Bricmont and Suresh Mallikaarjun

    Article first published online : 7 MAR 2013, DOI: 10.1177/0091270007307877

  7. Pharmacokinetic and Pharmacodynamic Interaction Between Tolvaptan and Warfarin in Healthy Subjects

    Clinical Pharmacology in Drug Development

    Volume 1, Issue 2, April 2012, Pages: 67–75, Susan E. Shoaf and Suresh Mallikaarjun

    Article first published online : 10 JAN 2013, DOI: 10.1177/2160763X12439702

  8. You have free access to this content
    Anidulafungin for the treatment of invasive candidiasis

    Clinical Microbiology and Infection

    Volume 17, Issue s1, March 2011, Pages: 1–12, A. Mayr, M. Aigner and C. Lass-Flörl

    Article first published online : 20 JAN 2011, DOI: 10.1111/j.1469-0691.2010.03448.x

  9. Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis

    British Journal of Clinical Pharmacology

    Volume 78, Issue 2, August 2014, Pages: 258–273, Richard M. Turner, Chun S. Kwok, Chen Chen-Turner, Chinedu A. Maduakor, Sonal Singh and Yoon K. Loke

    Article first published online : 21 JUL 2014, DOI: 10.1111/bcp.12306

  10. You have full text access to this OnlineOpen article
    A repeat-dose thorough QT study of inhaled fluticasone furoate/vilanterol combination in healthy subjects

    British Journal of Clinical Pharmacology

    Volume 77, Issue 3, March 2014, Pages: 466–479, Rodger Kempsford, Ann Allen, Kathryn Kelly, Parminder Saggu and Courtney Crim

    Article first published online : 21 FEB 2014, DOI: 10.1111/bcp.12243

  11. The safety and efficacy of long-term tolvaptan therapy for decompensated liver cirrhosis

    Hepatology Research

    Accepted manuscript online: 29 JUN 2015, Tomomi Kogiso, Katsutoshi Tokushige, Etsuko Hashimoto, Yuichi Ikarashi, Kazuhisa Kodama, Makiko Taniai, Nobuyuki Torii and Keiko Shiratori

    DOI: 10.1111/hepr.12547

  12. Review of Tolvaptan for Autosomal Dominant Polycystic Kidney Disease

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 34, Issue 6, June 2014, Pages: 605–616, Brian P. Baur and Calvin J. Meaney

    Article first published online : 7 APR 2014, DOI: 10.1002/phar.1421

  13. Systemic therapies containing ethanol and gelatine excipients

    British Journal of Dermatology

    Volume 163, Issue 4, October 2010, Pages: 885–886, P.M. Laws and R.B. Warren

    Article first published online : 31 MAY 2010, DOI: 10.1111/j.1365-2133.2010.09882.x

  14. Tolvaptan, an orally active non-peptide arginine vasopressin V2 receptor antagonist, reduces ascites in rats with chronic liver injury

    Hepatology Research

    Volume 43, Issue 11, November 2013, Pages: 1224–1230, Toshiki Miyazaki, Hiroyuki Fujiki and Yoshitaka Yamamura

    Article first published online : 17 FEB 2013, DOI: 10.1111/hepr.12073

  15. You have free access to this content
    New treatments for autosomal dominant polycystic kidney disease

    British Journal of Clinical Pharmacology

    Volume 76, Issue 4, October 2013, Pages: 524–535, Ming-Yang Chang and Albert C. M. Ong

    Article first published online : 24 SEP 2013, DOI: 10.1111/bcp.12136

  16. Dose-finding trial of tolvaptan in liver cirrhosis patients with hepatic edema: A randomized, double-blind, placebo-controlled trial

    Hepatology Research

    Volume 44, Issue 1, January 2014, Pages: 83–91, Kiwamu Okita, Seiji Kawazoe, Chitomi Hasebe, Kozo Kajimura, Akira Kaneko, Mitsuru Okada, Isao Sakaida and ASCITES Dose-Finding Trial Group

    Article first published online : 26 MAR 2013, DOI: 10.1111/hepr.12099

  17. You have free access to this content
    Tolvaptan, an Orally Active Vasopressin V2-Receptor Antagonist—Pharmacology and Clinical Trials

    Cardiovascular Drug Reviews

    Volume 25, Issue 1, Spring 2007, Pages: 1–13, Toshiki Miyazaki, Hiroyuki Fujiki, Yoshitaka Yamamura, Shigeki Nakamura and Toyoki Mori

    Article first published online : 13 APR 2007, DOI: 10.1111/j.1527-3466.2007.00001.x

  18. You have free access to this content
    Fentanyl Pharmacokinetics is not Dependent on Hepatic Uptake by Organic Anion-Transporting Polypeptide 1B1 in Human Beings

    Basic & Clinical Pharmacology & Toxicology

    Volume 113, Issue 1, July 2013, Pages: 43–48, Victoria C. Ziesenitz, Sonja K. König, Nina Mahlke, Ricarda Jantos, Gisela Skopp, Johanna Weiss, Walter E. Haefeli and Gerd Mikus

    Article first published online : 6 APR 2013, DOI: 10.1111/bcpt.12066

  19. Is tolvaptan indicated for refractory oedema in nephrotic syndrome?

    Nephrology

    Volume 20, Issue 2, February 2015, Pages: 103–106, Eun-Sik Park, Youn-sung Huh and Gheun-Ho Kim

    Article first published online : 24 JAN 2015, DOI: 10.1111/nep.12348

  20. Population pharmacokinetics of tolvaptan in healthy subjects and patients with hyponatremia secondary to congestive heart failure or hepatic cirrhosis

    Biopharmaceutics & Drug Disposition

    Volume 34, Issue 6, September 2013, Pages: 336–347, Scott A. Van Wart, Susan E. Shoaf, Suresh Mallikaarjun and Donald E. Mager

    Article first published online : 6 AUG 2013, DOI: 10.1002/bdd.1849